U.S. markets closed
  • S&P Futures

    4,122.00
    -2.50 (-0.06%)
     
  • Dow Futures

    32,726.00
    -11.00 (-0.03%)
     
  • Nasdaq Futures

    13,020.50
    -11.00 (-0.08%)
     
  • Russell 2000 Futures

    1,913.30
    -1.30 (-0.07%)
     
  • Crude Oil

    90.33
    -0.17 (-0.19%)
     
  • Gold

    1,808.40
    -3.90 (-0.22%)
     
  • Silver

    20.47
    -0.02 (-0.08%)
     
  • EUR/USD

    1.0208
    -0.0009 (-0.09%)
     
  • 10-Yr Bond

    2.7970
    +0.0320 (+1.16%)
     
  • Vix

    21.77
    +0.48 (+2.25%)
     
  • GBP/USD

    1.2074
    -0.0002 (-0.02%)
     
  • USD/JPY

    135.2400
    +0.1240 (+0.09%)
     
  • BTC-USD

    22,955.84
    -891.64 (-3.74%)
     
  • CMC Crypto 200

    532.85
    -24.50 (-4.40%)
     
  • FTSE 100

    7,488.15
    +5.78 (+0.08%)
     
  • Nikkei 225

    27,772.70
    -227.26 (-0.81%)
     

What Kind Of Investors Own Most Of Sana Biotechnology, Inc. (NASDAQ:SANA)?

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Sana Biotechnology, Inc. (NASDAQ:SANA) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.

Sana Biotechnology is a pretty big company. It has a market capitalization of US$3.8b. Normally institutions would own a significant portion of a company this size. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. We can zoom in on the different ownership groups, to learn more about Sana Biotechnology.

Check out our latest analysis for Sana Biotechnology

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Sana Biotechnology?

Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices.

As you can see, institutional investors have a fair amount of stake in Sana Biotechnology. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Sana Biotechnology's historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

Hedge funds don't have many shares in Sana Biotechnology. The company's largest shareholder is Arch Venture Partners, L.P., with ownership of 23%. Meanwhile, the second and third largest shareholders, hold 18% and 5.0%, of the shares outstanding, respectively. Additionally, the company's CEO Steven Harr directly holds 4.7% of the total shares outstanding.

On looking further, we found that 52% of the shares are owned by the top 4 shareholders. In other words, these shareholders have a meaningful say in the decisions of the company.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Sana Biotechnology

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our information suggests that insiders maintain a significant holding in Sana Biotechnology, Inc.. It is very interesting to see that insiders have a meaningful US$477m stake in this US$3.8b business. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.

General Public Ownership

The general public, with a 27% stake in the company, will not easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With an ownership of 42%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. For instance, we've identified 3 warning signs for Sana Biotechnology (1 is a bit unpleasant) that you should be aware of.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.